

## Notice of Company Update Webinar

**11 February 2025 – Melbourne, Australia: Neurizon Therapeutics Limited** (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce that it will host a webinar “Half-Year Update: Key Developments & Future Outlook”.

The webinar, hosted by Managing Director and Chief Executive Officer Dr. Michael Thurn, will offer valuable insights into Neurizon’s recent developments, ongoing progress, and strategic priorities.

**Date & Time:** Monday, February 17, 2025 at 3 PM AEDT

**Register at:** <https://bit.ly/NeurizonHY25>

Attendees are encouraged to submit their questions in advance, either during the registration process or by emailing [enquiries@neurizon.com](mailto:enquiries@neurizon.com).

A recording of the webinar will be available on Neurizon’s website after its completion.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

**Dr. Michael Thurn**

Managing Director and Chief Executive Officer  
Neurizon Therapeutics Limited  
[enquiries@neurizon.com](mailto:enquiries@neurizon.com)  
+61 (0) 396 927 222

**Lidija Damjanovic**

Head of Marketing and Corporate Affairs  
Neurizon Therapeutics Limited  
[lidija@neurizon.com](mailto:lidija@neurizon.com)  
+61 (0) 425 700 504

### About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

### Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>

